Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tanuja Chitnis, M.D.

Co-Author

This page shows the publications co-authored by Tanuja Chitnis and Howard Weiner.
Connection Strength

9.536
  1. CNS inflammation and neurodegeneration. J Clin Invest. 2017 Oct 02; 127(10):3577-3587.
    View in: PubMed
    Score: 0.725
  2. Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. Mult Scler J Exp Transl Clin. 2022 Jan-Mar; 8(1):20552173211069348.
    View in: PubMed
    Score: 0.245
  3. Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum. Front Neurol. 2021; 12:691683.
    View in: PubMed
    Score: 0.236
  4. Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis. Mult Scler Relat Disord. 2021 Sep; 54:103086.
    View in: PubMed
    Score: 0.236
  5. Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):20552173211015503.
    View in: PubMed
    Score: 0.235
  6. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol. 2021 06; 89(6):1195-1211.
    View in: PubMed
    Score: 0.233
  7. Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):2055217321999070.
    View in: PubMed
    Score: 0.233
  8. Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102910.
    View in: PubMed
    Score: 0.232
  9. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2021 03; 8(3):631-638.
    View in: PubMed
    Score: 0.229
  10. MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. J Neuroimaging. 2021 03; 31(2):388-393.
    View in: PubMed
    Score: 0.229
  11. Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol. 2020 12; 7(12):2508-2523.
    View in: PubMed
    Score: 0.226
  12. Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain. 2020 09 01; 143(9):2733-2741.
    View in: PubMed
    Score: 0.223
  13. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol. 2020 06; 7(6):945-955.
    View in: PubMed
    Score: 0.219
  14. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019; 2:123.
    View in: PubMed
    Score: 0.212
  15. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019 Dec 11; 2(1):123.
    View in: PubMed
    Score: 0.212
  16. ?d T Cell-Secreted XCL1 Mediates Anti-CD3-Induced Oral Tolerance. J Immunol. 2019 11 15; 203(10):2621-2629.
    View in: PubMed
    Score: 0.209
  17. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019 Oct; 35:119-127.
    View in: PubMed
    Score: 0.207
  18. Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. Mult Scler J Exp Transl Clin. 2019 Jan-Mar; 5(1):2055217319828400.
    View in: PubMed
    Score: 0.201
  19. Food allergies are associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019 06; 90(6):629-635.
    View in: PubMed
    Score: 0.198
  20. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1478-1491.
    View in: PubMed
    Score: 0.196
  21. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. J Neurol Sci. 2018 11 15; 394:127-131.
    View in: PubMed
    Score: 0.195
  22. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Mult Scler Relat Disord. 2018 Feb; 20:51-57.
    View in: PubMed
    Score: 0.185
  23. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Mult Scler Relat Disord. 2017 Oct; 17:47-53.
    View in: PubMed
    Score: 0.179
  24. Exploration of machine learning techniques in predicting multiple sclerosis disease course. PLoS One. 2017; 12(4):e0174866.
    View in: PubMed
    Score: 0.176
  25. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016 06 28; 7:12015.
    View in: PubMed
    Score: 0.167
  26. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e167.
    View in: PubMed
    Score: 0.159
  27. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015 Feb; 72(2):152-8.
    View in: PubMed
    Score: 0.151
  28. Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology. 2014 Jun 17; 82(24):2173-9.
    View in: PubMed
    Score: 0.144
  29. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014 Oct; 20(12):1584-92.
    View in: PubMed
    Score: 0.143
  30. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013 Nov 11; 13:172.
    View in: PubMed
    Score: 0.139
  31. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013 Jun; 73(6):729-40.
    View in: PubMed
    Score: 0.136
  32. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2012 Jan; 83(1):38-43.
    View in: PubMed
    Score: 0.118
  33. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011 Jun 07; 76(23):1996-2001.
    View in: PubMed
    Score: 0.118
  34. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. J Neurol Sci. 2011 Apr 15; 303(1-2):109-13.
    View in: PubMed
    Score: 0.115
  35. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler. 2010 Dec; 16(12):1483-9.
    View in: PubMed
    Score: 0.111
  36. MicroRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance. J Clin Invest. 2022 Mar 17.
    View in: PubMed
    Score: 0.062
  37. Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022 03; 9(2).
    View in: PubMed
    Score: 0.061
  38. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Qual Life Res. 2021 Nov 16.
    View in: PubMed
    Score: 0.061
  39. Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis. JAMA Netw Open. 2021 11 01; 4(11):e2134627.
    View in: PubMed
    Score: 0.060
  40. Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Mult Scler Relat Disord. 2022 Jan; 57:103333.
    View in: PubMed
    Score: 0.060
  41. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):20552173211007523.
    View in: PubMed
    Score: 0.059
  42. Author Correction: Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. NPJ Digit Med. 2020 Nov 20; 3(1):155.
    View in: PubMed
    Score: 0.057
  43. Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. NPJ Digit Med. 2020; 3:135.
    View in: PubMed
    Score: 0.056
  44. Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. NPJ Digit Med. 2020 Oct 16; 3(1):135.
    View in: PubMed
    Score: 0.056
  45. Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. J Psychosom Res. 2020 11; 138:110252.
    View in: PubMed
    Score: 0.056
  46. An At-home Positive Psychology Intervention for Individuals with Multiple Sclerosis: A Phase 1 Randomized Controlled Trial. Int J MS Care. 2021 May-Jun; 23(3):128-134.
    View in: PubMed
    Score: 0.056
  47. Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
    View in: PubMed
    Score: 0.056
  48. Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. Mult Scler. 2021 04; 27(4):593-602.
    View in: PubMed
    Score: 0.054
  49. Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. Mult Scler Relat Disord. 2020 May; 40:101944.
    View in: PubMed
    Score: 0.053
  50. History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep. 2019 10 14; 9(1):14781.
    View in: PubMed
    Score: 0.052
  51. Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Mult Scler. 2020 11; 26(13):1708-1718.
    View in: PubMed
    Score: 0.052
  52. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. J Neurol Sci. 2019 Aug 15; 403:38-43.
    View in: PubMed
    Score: 0.051
  53. Time between expanded disability status scale (EDSS) scores. Mult Scler Relat Disord. 2019 May; 30:98-103.
    View in: PubMed
    Score: 0.050
  54. Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. Mult Scler. 2019 11; 25(13):1791-1799.
    View in: PubMed
    Score: 0.049
  55. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep; 5(5):e491.
    View in: PubMed
    Score: 0.048
  56. Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. eNeurologicalSci. 2018 Sep; 12:42-46.
    View in: PubMed
    Score: 0.048
  57. Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis. Int J MS Care. 2018 May-Jun; 20(3):136-141.
    View in: PubMed
    Score: 0.047
  58. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018 Aug; 58(2):261-269.
    View in: PubMed
    Score: 0.047
  59. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci. 2017 Dec 15; 383:221-229.
    View in: PubMed
    Score: 0.046
  60. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017 Nov; 18:196-201.
    View in: PubMed
    Score: 0.046
  61. SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Mult Scler. 2018 10; 24(11):1485-1498.
    View in: PubMed
    Score: 0.045
  62. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.044
  63. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurol. 2017 03 01; 74(3):275-285.
    View in: PubMed
    Score: 0.044
  64. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. Int J Neurosci. 2017 Nov; 127(11):971-980.
    View in: PubMed
    Score: 0.044
  65. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e267.
    View in: PubMed
    Score: 0.042
  66. Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. J Neuroinflammation. 2015 Dec 30; 12:245.
    View in: PubMed
    Score: 0.040
  67. Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Ann Neurol. 2016 Feb; 79(2):178-89.
    View in: PubMed
    Score: 0.040
  68. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. J Neuroimaging. 2016 Mar-Apr; 26(2):184-7.
    View in: PubMed
    Score: 0.040
  69. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol. 2015 Nov; 262(11):2425-32.
    View in: PubMed
    Score: 0.039
  70. Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. Neuroimage Clin. 2015; 8:606-10.
    View in: PubMed
    Score: 0.039
  71. Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. Neuroimage. 2015 Oct 01; 119:81-8.
    View in: PubMed
    Score: 0.039
  72. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.037
  73. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler. 2014 Sep; 20(10):1381-90.
    View in: PubMed
    Score: 0.036
  74. Treatment satisfaction in multiple sclerosis. Int J MS Care. 2014; 16(2):68-75.
    View in: PubMed
    Score: 0.035
  75. Modeling disease severity in multiple sclerosis using electronic health records. PLoS One. 2013; 8(11):e78927.
    View in: PubMed
    Score: 0.035
  76. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.035
  77. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler. 2014 Apr; 20(4):438-44.
    View in: PubMed
    Score: 0.034
  78. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One. 2013; 8(3):e59707.
    View in: PubMed
    Score: 0.033
  79. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health. 2012 Dec; 15(8):1029-35.
    View in: PubMed
    Score: 0.032
  80. The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1579-85.
    View in: PubMed
    Score: 0.031
  81. The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Qual Life Res. 2012 Dec; 21(10):1677-84.
    View in: PubMed
    Score: 0.031
  82. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.031
  83. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 Oct; 82(10):1125-31.
    View in: PubMed
    Score: 0.029
  84. Patient reported outcomes in benign multiple sclerosis. Mult Scler. 2011 Jul; 17(7):876-84.
    View in: PubMed
    Score: 0.029
  85. A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One. 2010 Nov 30; 5(11):e14169.
    View in: PubMed
    Score: 0.028
  86. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 Apr; 233(1-2):168-74.
    View in: PubMed
    Score: 0.028
  87. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.028
  88. Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data. AJNR Am J Neuroradiol. 2009 Oct; 30(9):1731-9.
    View in: PubMed
    Score: 0.026
  89. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.